PanGen Biotech Balance Sheet Health
Financial Health criteria checks 6/6
PanGen Biotech has a total shareholder equity of ₩16.6B and total debt of ₩2.1B, which brings its debt-to-equity ratio to 12.6%. Its total assets and total liabilities are ₩24.4B and ₩7.7B respectively.
Key information
12.6%
Debt to equity ratio
₩2.10b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩4.34b |
| Equity | ₩16.63b |
| Total liabilities | ₩7.73b |
| Total assets | ₩24.36b |
Financial Position Analysis
Short Term Liabilities: A222110's short term assets (₩13.9B) exceed its short term liabilities (₩5.2B).
Long Term Liabilities: A222110's short term assets (₩13.9B) exceed its long term liabilities (₩2.5B).
Debt to Equity History and Analysis
Debt Level: A222110 has more cash than its total debt.
Reducing Debt: A222110's debt to equity ratio has reduced from 64.5% to 12.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A222110 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A222110 has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 3.3% each year.